Detection of SARS-COV-2-S antibody in solid organ transplantation recipients of Mongolia after mRNA vaccination
- VernacularTitle:Цуллаг эрхтэн шилжүүлэн суулгуулсан реципиентүүдэд мРНХ вакцины дараа anti-SARS-CoV2-S эсрэгбие тодорхойлсон нь
- Author:
Oyunbileg B
1
;
Sarantsetseg J
1
;
Bayan-Undur D
2
Author Information
1. Department of Laboratory Medicine, FCHM
2. Center of Urology and Andrology, FCHM
- Publication Type:Journal Article
- Keywords:
SARS-CoV-2-S IgG antibody;
COVID-19 disease;
mRNA;
humoral immune response
- From:
Health Laboratory
2021;14(2):17-22
- CountryMongolia
- Language:Mongolian
-
Abstract:
Introduction:The Severe Acute Respiratory Syndrome coronavirus-2 has a major impact in solid organ transplant recipients and the effect of established mRNA based SARS-CoV-2 vaccines have to be evaluated for solid organ transplant patients (SOT) since they are known to have poor responses after vaccination.
Method:We investigated the SARSCoV-2 immune response via SARS-CoV-2 S IgG detection in the serum of 17 renal transplant recipients and 11 liver transplant recipients after two doses of the mRNA based SARS-CoV-2 vaccine BNT162b2 following the standart protocol.
Result:The median age was 52.5±12 years. Nineteen (67.8%) of the 28 patients were male, and 9 (32.2%) were female. The mean time after organ transplantation was 6.3±5 years (5 months-16 years). The immunosuppressive regimen included mycophenolate (19 of 28; 67.8%), tacrolimus (27 of 28; 96.4%), and corticosteroids (15 of 28; 53.6%).
The antibody response was evaluated once with an anti- SARS-CoV-2-S IgG CLIA (Elecsys Roche, Germany) 30±2 days after the second dose. Only 19 of 28 (67.8%) SOTRs were tested positive for SARS-CoV-2-S IgG after the second dose of vaccine and median titer was 119.5±106.4 Н/мл.
Conclusion:Thus, the humoral response of SOTRs after two doses of the mRNA based SARS-CoV-2 vaccine BNT162b2 is impaired. Individual vaccination strategies and third dose of vaccine might be beneficial in these vulnerable patients.
- Full text:HL-2021-14(2)-17-22.pdf
